glp-1 news today receptor agonists show promise in treating substance use disorders FDA priority vouchers for GLP-1

It is estimated that nearly 60% of depressive episodes are preceded by an exposure to various types of stressors [69]

and semaglutide injections may have a slightly larger effect than oral semaglutide

Important safety considerations include the risk of pancreatitis (all GLP-1 agonists carry warnings about this), gallbladder disease (more common with greater weight loss), and a caution with semaglutide in patients with pre-existing diabetic retinopathy, where rapid improvement in glucose control may temporarily worsen retinopathy

Reduces the Risk of Rebound Weight Gain Clinical follow-up shows that GLP-1 users commonly regain 6690% of lost weight within one year after stopping injections